Key Drivers
- Cash Cushion
- Loss Burden
- Dilution Risk
AIAI Summary
IMTX's thesis has shifted from a single melanoma bet to a broader PRAME oncology platform with anzu-cel as the near-term catalyst, and while its strong cash runway into 2028 reduces financing risk, the stock still looks like a high-risk, catalyst-driven biotech that will only re-rate if clinical data validate durable efficacy and tolerability across multiple programs.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Loss Burden
- •Dilution Risk
IMTX has a strong cash position and minimal leverage, but persistent heavy losses and burn mean the stock is financially resilient yet still highly execution-risky.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance cap
- •Support cluster
Over the last month, IMTX has recovered from its $8.87 low with a series of higher lows and improving momentum, but it remains range-bound below $10.13-$10.20 resistance until it can hold above $10.00.
Dropped to $8.87 before rebounding toward $10.00
Sentiment & News
Key News Insights:
- •PRAME Platform
- •Phase 3 Progress
- •Strong Cash Runway
Immatics is evolving from a single-asset cell therapy story into a broader PRAME oncology platform, with anzu-cel still in Phase 3 for melanoma and cash runway extending into 2028.
The update is modestly positive for IMTX, as it expands the company's long-term growth story while supporting near-term clinical execution with solid funding
Similar Companies in Healthcare
Other companies in the same sector with AI ratings